Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cleavage and polyadenylation specificity factor 4 (CPSF4, also known as CPSF30 or NEB1) is a 30 kDa protein component of the CPSF complex, critically involved in 3'-end processing and polyadenylation of pre-mRNA[1][2][3]. It contains several zinc finger motifs and recognizes the polyadenylation signal on pre-mRNA, aiding in cleavage and polyadenylation[2]. CPSF4 regulates RNA maturation and, through these functions, impacts cell proliferation and apoptosis; its overexpression in lung adenocarcinoma is associated with poor prognosis, while its inhibition suppresses tumor growth[1]. CPSF4 interacts with the influenza virus NS1 protein, which blocks host cell mRNA processing to support viral replication[3]. Although not currently a therapeutic drug target, CPSF4 has potential as a prognostic biomarker and possible future target in oncology[1].
Not directly targeted by any approved drugs; functional inhibition (e.g., by siRNA) can reduce tumor growth and promote apoptosis[1]. The influenza A NS1 protein inhibits its function during viral infection[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cleavage and polyadenylation specificity factor 4 (CPSF4).